FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582448936> ?p ?o ?g. }

• W2582448936 endingPage "16898" @default.
• W2582448936 startingPage "16887" @default.
• W2582448936 abstract "// Mariantonietta Di Salvatore 1 , Filippo Pietrantonio 2 , Armando Orlandi 1 , Marzia Del Re 3 , Rosa Berenato 2 , Ernesto Rossi 1 , Marta Caporale 2 , Donatella Guarino 4 , Antonia Martinetti 2 , Michele Basso 1 , Roberta Mennitto 2 , Concetta Santonocito 4 , Alessia Mennitto 2 , Giovanni Schinzari 1 , Ilaria Bossi 2 , Ettore Capoluongo 4 , Romano Danesi 3 , Filippo de Braud 2 , Carlo Barone 1 1 Unit of Clinical Oncology, Università Cattolica del Sacro Cuore, 00168 Rome, Italy 2 Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy 3 Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy 4 Laboratory of Clinical Molecular Biology, Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy Correspondence to: Mariantonietta Di Salvatore, email: mariantonietta.disalvatore@gmail.com Keywords: single nucleotid polymorphisms, bevacizumab, IL-8, eNOS, colorectal cancer Received: May 23, 2016      Accepted: November 02, 2016      Published: January 25, 2017 ABSTRACT Background : Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. Methods: 120 patients treated with first-line combination FOLFOX6 plus bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group. The following SNPs were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels and bevacizumab-efficacy was done. Results : In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P<0.001) compared to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had significantly higher IL-8 levels (P<0.0001). Multivariate analysis confirmed association of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients carrying the c.-894TT genotype. Conclusions : Although our data need prospective validation, IL-8 and eNOS SNPs may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity." @default.
• W2582448936 created "2017-02-03" @default.
• W2582448936 creator A5004635457 @default.
• W2582448936 creator A5006457492 @default.
• W2582448936 creator A5008284643 @default.
• W2582448936 creator A5011884019 @default.
• W2582448936 creator A5012446712 @default.
• W2582448936 creator A5019125073 @default.
• W2582448936 creator A5021598353 @default.
• W2582448936 creator A5030848899 @default.
• W2582448936 creator A5033675152 @default.
• W2582448936 creator A5038576978 @default.
• W2582448936 creator A5045768721 @default.
• W2582448936 creator A5052353123 @default.
• W2582448936 creator A5056273091 @default.
• W2582448936 creator A5059201916 @default.
• W2582448936 creator A5066923986 @default.
• W2582448936 creator A5073293203 @default.
• W2582448936 creator A5077861873 @default.
• W2582448936 creator A5079437223 @default.
• W2582448936 creator A5083693387 @default.
• W2582448936 date "2017-01-25" @default.
• W2582448936 modified "2023-10-18" @default.
• W2582448936 title "IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients" @default.
• W2582448936 cites W130706722 @default.
• W2582448936 cites W15366152 @default.
• W2582448936 cites W1954343133 @default.
• W2582448936 cites W1964333967 @default.
• W2582448936 cites W1987576919 @default.
• W2582448936 cites W2016016054 @default.
• W2582448936 cites W2025097579 @default.
• W2582448936 cites W2029790299 @default.
• W2582448936 cites W2032562223 @default.
• W2582448936 cites W2034282331 @default.
• W2582448936 cites W2042884540 @default.
• W2582448936 cites W2055192249 @default.
• W2582448936 cites W2064424253 @default.
• W2582448936 cites W2071549019 @default.
• W2582448936 cites W2075304664 @default.
• W2582448936 cites W2077884273 @default.
• W2582448936 cites W2079654264 @default.
• W2582448936 cites W2081238655 @default.
• W2582448936 cites W2108100419 @default.
• W2582448936 cites W2110162765 @default.
• W2582448936 cites W2110554565 @default.
• W2582448936 cites W2111419867 @default.
• W2582448936 cites W2115162283 @default.
• W2582448936 cites W2122730895 @default.
• W2582448936 cites W2130501081 @default.
• W2582448936 cites W2142943611 @default.
• W2582448936 cites W2144262617 @default.
• W2582448936 cites W2148802162 @default.
• W2582448936 cites W2149254095 @default.
• W2582448936 cites W2153726078 @default.
• W2582448936 cites W2157019123 @default.
• W2582448936 cites W2165262695 @default.
• W2582448936 cites W2170446482 @default.
• W2582448936 cites W2187403206 @default.
• W2582448936 cites W2406309081 @default.
• W2582448936 cites W2028817335 @default.
• W2582448936 doi "https://doi.org/10.18632/oncotarget.14810" @default.
• W2582448936 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5370008" @default.
• W2582448936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28129643" @default.
• W2582448936 hasPublicationYear "2017" @default.
• W2582448936 type Work @default.
• W2582448936 sameAs 2582448936 @default.
• W2582448936 citedByCount "27" @default.
• W2582448936 countsByYear W25824489362018 @default.
• W2582448936 countsByYear W25824489362019 @default.
• W2582448936 countsByYear W25824489362020 @default.
• W2582448936 countsByYear W25824489362021 @default.
• W2582448936 countsByYear W25824489362022 @default.
• W2582448936 crossrefType "journal-article" @default.
• W2582448936 hasAuthorship W2582448936A5004635457 @default.
• W2582448936 hasAuthorship W2582448936A5006457492 @default.
• W2582448936 hasAuthorship W2582448936A5008284643 @default.
• W2582448936 hasAuthorship W2582448936A5011884019 @default.
• W2582448936 hasAuthorship W2582448936A5012446712 @default.
• W2582448936 hasAuthorship W2582448936A5019125073 @default.
• W2582448936 hasAuthorship W2582448936A5021598353 @default.
• W2582448936 hasAuthorship W2582448936A5030848899 @default.
• W2582448936 hasAuthorship W2582448936A5033675152 @default.
• W2582448936 hasAuthorship W2582448936A5038576978 @default.
• W2582448936 hasAuthorship W2582448936A5045768721 @default.
• W2582448936 hasAuthorship W2582448936A5052353123 @default.
• W2582448936 hasAuthorship W2582448936A5056273091 @default.
• W2582448936 hasAuthorship W2582448936A5059201916 @default.
• W2582448936 hasAuthorship W2582448936A5066923986 @default.
• W2582448936 hasAuthorship W2582448936A5073293203 @default.
• W2582448936 hasAuthorship W2582448936A5077861873 @default.
• W2582448936 hasAuthorship W2582448936A5079437223 @default.
• W2582448936 hasAuthorship W2582448936A5083693387 @default.
• W2582448936 hasBestOaLocation W25824489361 @default.
• W2582448936 hasConcept C121608353 @default.
• W2582448936 hasConcept C126322002 @default.
• W2582448936 hasConcept C143998085 @default.
• W2582448936 hasConcept C2776694085 @default.
• W2582448936 hasConcept C2777622882 @default.

• next